{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:02:41Z","timestamp":1792587761911,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10,5]]},"DOI":"10.4103\/0366-6999.166038","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T09:24:33Z","timestamp":1443086673000},"page":"2625-2631","source":"Crossref","is-referenced-by-count":13,"title":["Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-na\u00efve Patients Infected with Genotype 1b Hepatitis C Virus"],"prefix":"10.1097","volume":"128","author":[{"given":"Ye","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ying","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Wang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/j.gastro.2014.03.008","article-title":"Impact of new hepatitis C treatments in different regions of the world","volume":"146","author":"Wei","year":"2014","journal-title":"Gastroenterology"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","article-title":"New horizons in hepatitis C antiviral therapy with direct-acting antivirals","volume":"58","author":"Aghemo","year":"2013","journal-title":"Hepatology"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1478-3231.2009.02156.x","article-title":"Hepatitis C treatment completion rates in routine clinical care","volume":"30","author":"Butt","year":"2010","journal-title":"Liver Int"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: The toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.coviro.2011.10.001","article-title":"Resistance to anti-HCV protease inhibitors","volume":"1","author":"Thompson","year":"2011","journal-title":"Curr Opin Virol"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/infdis\/jis761","article-title":"Antiviral resistance and the future landscape of hepatitis C virus infection therapy","volume":"207","author":"Wyles","year":"2013","journal-title":"J Infect Dis"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","article-title":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: A randomised study","volume":"64","author":"H\u00e9zode","year":"2015","journal-title":"Gut"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","article-title":"Simeprevir with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial","volume":"61","author":"Hayashi","year":"2014","journal-title":"J Hepatol"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","article-title":"Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies","volume":"49","author":"Izumi","year":"2014","journal-title":"J Gastroenterol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2014.02.019","article-title":"Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure","volume":"105","author":"Macartney","year":"2014","journal-title":"Antiviral Res"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1743-422X-10-57","article-title":"Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: A prospective longitudinal study","volume":"10","author":"Hoffmann","year":"2013","journal-title":"Virol J"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.04.018","article-title":"Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a","volume":"99","author":"Palanisamy","year":"2013","journal-title":"Antiviral Res"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jvh.12271","article-title":"Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1","volume":"22","author":"Kosaka","year":"2015","journal-title":"J Viral Hepat"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","article-title":"Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): A randomised, open-label phase 2 trial","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","article-title":"Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir","volume":"58","author":"Karino","year":"2013","journal-title":"J Hepatol"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm401398x","article-title":"Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A","volume":"57","author":"DeGoey","year":"2014","journal-title":"J Med Chem"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jvh.12230","article-title":"Importance of HCV genotype 1 subtypes for drug resistance and response to therapy","volume":"21","author":"Wyles","year":"2014","journal-title":"J Viral Hepat"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3851\/IMP2729","article-title":"Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b","volume":"19","author":"McPhee","year":"2014","journal-title":"Antivir Ther"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1517\/14656566.2014.972364","article-title":"Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C","volume":"15","author":"Stirnimann","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/gutjnl-2013-305771","article-title":"New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C","volume":"63","author":"Mari\u00f1o","year":"2014","journal-title":"Gut"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/jvh.12051","article-title":"The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank","volume":"20","author":"Alves","year":"2013","journal-title":"J Viral Hepat"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1743-422X-9-214","article-title":"Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates","volume":"9","author":"Jaspe","year":"2012","journal-title":"Virol J"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.12.037","article-title":"Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations","volume":"477","author":"Ji","year":"2015","journal-title":"Virology"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.166038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:36:21Z","timestamp":1623958581000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201510050-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,5]]},"references-count":33,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.166038","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10,5]]}}}